Finasteride vs Dutasteride and Tamsulosin — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

5-alpha Reductase Inhibitor

Finasteride

Brand: PROPECIA

First FDA approval: 2006-12-15

5-alpha Reductase Inhibitor

Dutasteride and Tamsulosin

Brand: Jalyn

First FDA approval: 2015-11-18

Lowest NADACAcquisition cost floor across all NDCs

$0.041Per unit

$2.02Per unit

Average NADACAcross all dosage forms and strengths

$0.438Up to $5.72

$2.02Up to $2.02

Generic manufacturersActive ANDA holders — FDA Orange Book

914 total ANDAs filed

33 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$144.5MFull year

—Full year

Part D claims (CY24)Total fills, all strengths

11.2M3.5M beneficiaries

—— beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$13Per claim, all NDCs

—Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

DiscontinuedSee drug profile

NoneClear

Generic availableFDA Orange Book

Yes9 manufacturers

Yes3 manufacturers